PT-141 Research: What 119 Studies Show (2026) | RetatrutideCompare

PT-141 — 119 studies indexed on PubMed. Non-selective melanocortin receptor agonist (MC1R, MC3R, MC4R). MC4R activation in the medial preoptic area drives sexual desire centrally. Half-life: ~2.7 hours (subcutaneous). FDA status: FDA-approved (2019).

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on PT-141?

There are approximately 119 studies indexed on PubMed that mention PT-141 (Bremelanotide, Vyleesi), based on a search last updated 2026-06-18.

Is PT-141 FDA-approved?

FDA status: FDA-approved (2019).

How does PT-141 work?

Non-selective melanocortin receptor agonist (MC1R, MC3R, MC4R). MC4R activation in the medial preoptic area drives sexual desire centrally.

Reference facts

Also known as: Bremelanotide, Vyleesi
Category: Sexual Health & MSH
Mechanism of action: Non-selective melanocortin receptor agonist (MC1R, MC3R, MC4R). MC4R activation in the medial preoptic area drives sexual desire centrally.
Targets: MC4R, MC3R, MC1R
Indications under research or approved: Hypoactive Sexual Desire Disorder (HSDD) in pre-menopausal women
Regulatory status (reference entry): FDA-approved (2019)
Half-life: ~2.7 hours (subcutaneous)
Sequence notes: Cyclic heptapeptide Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH derived from α-MSH.
Molecular weight (Da): 1025
Originator / sponsor: AMAG / Palatin Technologies
First reported: 2003

Primary References

Vyleesi FDA label

Explore research articles about PT-141

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.